Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Non-Small Cell Lung: early-phase trial registry
43 of 133 indexed Carcinoma, Non-Small Cell Lung trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #86 of 28,707 conditions by registered trial count.
133 US clinical trials · 43 currently recruiting · #86 of 28,707 conditions by registered trial count
Carcinoma, Non-Small Cell Lung: 133 US clinical trials tracked, 43 recruiting.
Carcinoma, Non-Small Cell Lung is the subject of 133 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 14 of these trials.
Enrollment posture brief
Registry condition carcinoma-non-small-cell-lung
OPEN 43 | RECR 32% | LATE 27 | EARLY 92 | RANK #86 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IIIB Breast Cancer AJCC v8 (32% recruiting · 34 trials)
Carcinoma, Non-Small Cell Lung lists 43 open slots (32% of 133 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Non-Small Cell Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Non-Small Cell Lung is recruiting below its size-band peers.
43 of 133 indexed trials (32.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Carcinoma, Non-Small Cell Lung trials is spread across many organizations.
Pfizer accounts for 14 of 133 trials (10.5%). 59 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma, Non-Small Cell Lung enrolment sits around 126 participants.
Median target enrolment is 126 among the 131 trials that report a genuine target (sentinel values excluded). 58 of those (44.3%) plan for fewer than 100 participants.
-
Carcinoma, Non-Small Cell Lung research is mostly interventional.
123 interventional and 10 observational studies make up this index (92.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
133 total, page 3 of 3
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Memorial Sloan Kettering Cancer Center
NCT00130780
Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
Eli Lilly and Company
NCT00191230
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
Seagen
NCT00051571
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
MedImmune
NCT02088112
Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer
Fox Chase Cancer Center
NCT00315185
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Eli Lilly and Company
NCT00051493
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00001499
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Ahmad Tarhini
NCT01233687
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00063219
Healthy Directions After Lung Surgery Pilot
Dana-Farber Cancer Institute
NCT02135211
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Kadmon Corporation
NCT00522145
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Bristol-Myers Squibb
NCT00441337
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
BioNTech US
NCT03380871
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Cancer Institute (NCI)
NCT00923481
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
Boehringer Ingelheim
NCT01647711
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study
Clinical Oncology Research Associates
NCT00256815
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
Sanofi
NCT00819728
Natural Killer Cells and Bortezomib to Treat Cancer
National Heart, Lung, and Blood Institute (NHLBI)
NCT00720785
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
Janssen Research & Development
NCT04951154
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
NCT00043368
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02897778
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02909452
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
G1 Therapeutics
NCT03455829
Once Weekly Radiation for Lung Cancer With Chemotherapy
Clinical Oncology Research Associates
NCT00256789
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
Washington University School of Medicine
NCT02172846
BIO 300 Non-Small Cell Lung Cancer Study
Humanetics Corporation
NCT02567799
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
NCT04452214
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Novartis Pharmaceuticals
NCT03647488
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
NCT00946673
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
Active Biotech AB
NCT00132379
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT03023319
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
Pfizer
NCT00034957
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy
R-Pharm
NCT00035516
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 34 |
| Phase 3 | 27 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Non-Small Cell Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Non-Small Cell Lung trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Non-Small Cell Lung page
133 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Carcinoma, Non-Small Cell Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Carcinoma, Non-Small Cell Lung trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Non-Small Cell Lung condition card totals 133 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.